Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy

Research on the relationship between microbiome and cancer has made significant progress in the past few decades. It is now known that the gut microbiome has multiple effects on tumour biology. However, the relationship between intratumoral bacteria and cancers remains unclear. Growing evidence sugg...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiawen Chen, Ting Li, Jianhao Liang, Qiqi Huang, Jian-Dong Huang, Yiquan Ke, Haitao Sun
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Intratumoral bacteria Genetically engineered bacteria Tumor Therapy Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/b89b75236a1b417fb182804cc3109dff
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b89b75236a1b417fb182804cc3109dff
record_format	dspace
spelling	oai:doaj.org-article:b89b75236a1b417fb182804cc3109dff2021-11-28T04:28:10ZCurrent status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy0753-332210.1016/j.biopha.2021.112443https://doaj.org/article/b89b75236a1b417fb182804cc3109dff2022-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S0753332221012294https://doaj.org/toc/0753-3322Research on the relationship between microbiome and cancer has made significant progress in the past few decades. It is now known that the gut microbiome has multiple effects on tumour biology. However, the relationship between intratumoral bacteria and cancers remains unclear. Growing evidence suggests that intratumoral bacteria are important components of the microenvironment in several types of cancers. Furthermore, several studies have demonstrated that intratumoral bacteria may directly influence tumorigenesis, progression and responses to treatment. Limited studies have been conducted on intratumoral bacteria, and using intratumoral bacteria to treat tumours remains a challenge. Bacteria have been studied as anticancer therapeutics since the 19th century when William B. Coley successfully treated patients with inoperable sarcomas using Streptococcus pyogenes. With the development of synthetic biological approaches, several bacterial species have been genetically engineered to increase their applicability for cancer treatment. Genetically engineered bacteria for cancer therapy have unique properties compared to other treatment methods. They can specifically accumulate within tumours and inhibit cancer growth. In addition, genetically engineered bacteria may be used as a vector to deliver antitumour agents or combined with radiation and chemotherapy to synergise the effectiveness of cancer treatment. However, various problems in treating tumours with genetically engineered bacteria need to be addressed. In this review, we focus on the role of intratumoral bacteria on tumour initiation, progression and responses to chemotherapy or immunotherapy. Moreover, we summarised the recent progress in the treatment of tumours with genetically engineered bacteria.Jiawen ChenTing LiJianhao LiangQiqi HuangJian-Dong HuangYiquan KeHaitao SunElsevierarticleIntratumoral bacteriaGenetically engineered bacteriaTumorTherapyTherapeutics. PharmacologyRM1-950ENBiomedicine & Pharmacotherapy, Vol 145, Iss , Pp 112443- (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Intratumoral bacteria Genetically engineered bacteria Tumor Therapy Therapeutics. Pharmacology RM1-950
spellingShingle	Intratumoral bacteria Genetically engineered bacteria Tumor Therapy Therapeutics. Pharmacology RM1-950 Jiawen Chen Ting Li Jianhao Liang Qiqi Huang Jian-Dong Huang Yiquan Ke Haitao Sun Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy
description	Research on the relationship between microbiome and cancer has made significant progress in the past few decades. It is now known that the gut microbiome has multiple effects on tumour biology. However, the relationship between intratumoral bacteria and cancers remains unclear. Growing evidence suggests that intratumoral bacteria are important components of the microenvironment in several types of cancers. Furthermore, several studies have demonstrated that intratumoral bacteria may directly influence tumorigenesis, progression and responses to treatment. Limited studies have been conducted on intratumoral bacteria, and using intratumoral bacteria to treat tumours remains a challenge. Bacteria have been studied as anticancer therapeutics since the 19th century when William B. Coley successfully treated patients with inoperable sarcomas using Streptococcus pyogenes. With the development of synthetic biological approaches, several bacterial species have been genetically engineered to increase their applicability for cancer treatment. Genetically engineered bacteria for cancer therapy have unique properties compared to other treatment methods. They can specifically accumulate within tumours and inhibit cancer growth. In addition, genetically engineered bacteria may be used as a vector to deliver antitumour agents or combined with radiation and chemotherapy to synergise the effectiveness of cancer treatment. However, various problems in treating tumours with genetically engineered bacteria need to be addressed. In this review, we focus on the role of intratumoral bacteria on tumour initiation, progression and responses to chemotherapy or immunotherapy. Moreover, we summarised the recent progress in the treatment of tumours with genetically engineered bacteria.
format	article
author	Jiawen Chen Ting Li Jianhao Liang Qiqi Huang Jian-Dong Huang Yiquan Ke Haitao Sun
author_facet	Jiawen Chen Ting Li Jianhao Liang Qiqi Huang Jian-Dong Huang Yiquan Ke Haitao Sun
author_sort	Jiawen Chen
title	Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy
title_short	Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy
title_full	Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy
title_fullStr	Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy
title_full_unstemmed	Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy
title_sort	current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/b89b75236a1b417fb182804cc3109dff
work_keys_str_mv	AT jiawenchen currentstatusofintratumourmicrobiomeincancerandengineeredexogenousmicrobiotaasapromisingtherapeuticstrategy AT tingli currentstatusofintratumourmicrobiomeincancerandengineeredexogenousmicrobiotaasapromisingtherapeuticstrategy AT jianhaoliang currentstatusofintratumourmicrobiomeincancerandengineeredexogenousmicrobiotaasapromisingtherapeuticstrategy AT qiqihuang currentstatusofintratumourmicrobiomeincancerandengineeredexogenousmicrobiotaasapromisingtherapeuticstrategy AT jiandonghuang currentstatusofintratumourmicrobiomeincancerandengineeredexogenousmicrobiotaasapromisingtherapeuticstrategy AT yiquanke currentstatusofintratumourmicrobiomeincancerandengineeredexogenousmicrobiotaasapromisingtherapeuticstrategy AT haitaosun currentstatusofintratumourmicrobiomeincancerandengineeredexogenousmicrobiotaasapromisingtherapeuticstrategy
_version_	1718408402586042368

Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy

Ejemplares similares